Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.36 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19255556 | 0.81 | GSK3B (0.43) | PARP1GSK3BAKR1B1CREBBPBRPF1 | |
| SCHEMBL16651489 | 0.76 | GSK3B (0.38) | PARP1GSK3BAKR1B1OTUD7BCYP1A2 | |
| SCHEMBL26462499 | 0.76 | GSK3B (0.38) | PARP1GSK3BAKR1B1CREBBPBRPF1 | |
| SCHEMBL4067523 | 0.73 | PARP1 (0.56) | PARP1GSK3BAKR1B1PDE3BPDE3A | |
| SCHEMBL18128068 | 0.73 | PARP1 (0.44) | PARP1PDE3BPDE3AMAOBADORA2A | |
| SCHEMBL18128134 | 0.73 | PARP1 (0.56) | PARP1GSK3BAKR1B1PDE3BPDE3A | |
| SCHEMBL21261598 | 0.72 | PARP1 (0.46) | PARP1CREBBPBRPF1PDE3BPDE3A | |
| SCHEMBL21261375 | 0.72 | PARP1 (0.46) | PARP1CREBBPBRPF1PDE3BPDE3A | |
| SCHEMBL21261431 | 0.72 | PARP1 (0.46) | PARP1CREBBPBRPF1PDE3BPDE3A | |
| SCHEMBL1451025 | 0.72 | PARP1 (1.00) | PARP1CREBBPBRPF1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115867556-B | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2025-05-06 | — | — | CN | disclosed |
| US-11702407-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702407-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-4161936-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-115867556-A | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20210380561-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702407-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | PARP1 2255/4885GSK3B 1799/4885AKR1B1 361/4885 |
| US-20210380561-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | PARP1 2255/4885GSK3B 1799/4885AKR1B1 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.